Bhatt Padmanabh P.

CIK 00015392151 companyROCKVILLE, MD

SEC Profile

Transactions

Companies

Filings

CIK

0001539215

Recent Transactions

50 trades

Sale
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2026-03-18$49.55/sh−6,838→ 17,456 total
Sale
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2026-03-18$50.48/sh−412→ 17,044 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Employee Stock Option (Right to Buy)
2026-03-18−7,250→ 0 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2026-03-18$39.40/sh+7,250→ 24,294 total
Sale
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2026-03-17$49.95/sh−27,710→ 39,334 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Employee Stock Option (Right to Buy)
2026-03-17−22,750→ 7,250 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Employee Stock Option (Right to Buy)
2026-03-17−12,250→ 0 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Employee Stock Option (Right to Buy)
2026-03-17−15,000→ 5,000 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2026-03-17$36.75/sh+12,250→ 52,044 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2026-03-17$38.60/sh+15,000→ 67,044 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2026-03-17$39.40/sh+22,750→ 39,794 total
Sale
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2026-03-17$50.73/sh−22,290→ 17,044 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2026-03-16$27.94/sh+5,000→ 67,044 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Employee Stock Option (Right to Buy)
2026-03-16−5,000→ 15,000 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Employee Stock Option (Right to Buy)
2026-03-16−4,250→ 0 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Employee Stock Option (Right to Buy)
2026-03-16−18,000→ 0 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Employee Stock Option (Right to Buy)
2026-03-16−22,750→ 12,250 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2026-03-16$36.75/sh+22,750→ 39,794 total
Sale
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2026-03-16$50.18/sh−34,114→ 32,930 total
Sale
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2026-03-16$50.49/sh−15,886→ 17,044 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2026-03-16$32.20/sh+18,000→ 62,044 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2026-03-16$29.61/sh+4,250→ 44,044 total
Disposition to Issuer
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Restricted Stock Unit
2026-02-25−1,250→ 1,250 total
Tax Payment
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2026-02-25$50.69/sh−650→ 17,044 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2026-02-25+1,250→ 17,694 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2026-02-24+1,125→ 16,025 total
Tax Payment
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2026-02-24$50.86/sh−354→ 15,840 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2026-02-24+1,250→ 17,090 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2026-02-24+750→ 16,194 total
Tax Payment
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2026-02-24$51.35/sh−581→ 15,444 total
Disposition to Issuer
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Restricted Stock Unit
2026-02-24−1,250→ 2,500 total
Tax Payment
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2026-02-24$50.86/sh−646→ 16,444 total
Disposition to Issuer
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Restricted Stock Unit
2026-02-24−1,125→ 3,375 total
Disposition to Issuer
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Restricted Stock Unit
2026-02-24−750→ 0 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Restricted Stock Unit
2026-02-18+3,000→ 3,000 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Employee Stock Option (Right to Buy)
2026-02-18+13,500→ 13,500 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2025-12-18+1,500→ 15,218 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Performance Share Unit
2025-12-18−1,500→ 0 total
Sale
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2025-12-18$44.44/sh−710→ 14,508 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Performance Share Unit
2025-11-13+1,500→ 1,500 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Performance Share Unit
2025-08-25−1,250→ 0 total
Tax Payment
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2025-08-25$41.46/sh−581→ 13,718 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2025-08-25+1,250→ 14,299 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Performance Share Unit
2025-08-07+1,250→ 1,250 total
Tax Payment
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2025-03-05$33.05/sh−335→ 13,854 total
Tax Payment
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2025-03-05$33.05/sh−575→ 13,279 total
Tax Payment
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2025-03-05$33.05/sh−575→ 12,704 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2025-02-23+1,250→ 14,189 total
Disposition to Issuer
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Restricted Stock Unit
2025-02-23−1,250→ 2,500 total
Disposition to Issuer
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Restricted Stock Unit
2025-02-22−750→ 750 total

Companies

SUPERNUS PHARMACEUTICALS, INC.
Sr. VP of IP, CSO
$SUPN

Recent Filings

4
Bhatt Padmanabh P.
Mar 18, 2026

Address

C/O SUPERNUS PHARMACEUTICALS, INC. 9715 KEY WEST AVENUE

ROCKVILLE, MD, 20850

View on SEC.gov